Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent TaxesGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxNon-Current AssetsNon-Current DebtOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPreferred Stock LiabilitiesPrepaid AssetsProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShareholder's EquityShares OutstandingShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Ani Pharmaceuticals (ANIP) Other Non-Current Assets (2016 - 2026)

Ani Pharmaceuticals' Other Non-Current Assets history spans 14 years, with the latest figure at $13.7 million for Q4 2025.

  • On a quarterly basis, Other Non-Current Assets rose 12.16% to $13.7 million in Q4 2025 year-over-year; TTM through Dec 2025 was $13.7 million, a 12.16% increase, with the full-year FY2025 number at $13.7 million, up 12.16% from a year prior.
  • Other Non-Current Assets hit $13.7 million in Q4 2025 for Ani Pharmaceuticals, up from $12.5 million in the prior quarter.
  • Over the last five years, Other Non-Current Assets for ANIP hit a ceiling of $16.1 million in Q3 2023 and a floor of $2.2 million in Q4 2021.
  • Historically, Other Non-Current Assets has averaged $9.8 million across 5 years, with a median of $11.4 million in 2022.
  • Biggest five-year swings in Other Non-Current Assets: tumbled 55.93% in 2021 and later surged 415.24% in 2022.
  • Tracing ANIP's Other Non-Current Assets over 5 years: stood at $2.2 million in 2021, then surged by 415.24% to $11.4 million in 2022, then rose by 6.26% to $12.1 million in 2023, then grew by 1.23% to $12.2 million in 2024, then rose by 12.16% to $13.7 million in 2025.
  • Business Quant data shows Other Non-Current Assets for ANIP at $13.7 million in Q4 2025, $12.5 million in Q3 2025, and $8.2 million in Q2 2025.